Adenosine clearly regulates coronary blood flow (CBF); however, contributions of specific adenosine receptor (AR) subtypes (A 1 , A 2A , A 2B , A 3 ) to CBF in swine have not been determined.
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Adenosine contributes to maintenance of coronary blood flow (CBF), especially during myocardial ischemia (Tune, et al., 2004; Fredholm, et al., 2001; Duncker and Bache, 2008) and is used clinically to elicit maximal vasodilation to diagnose flow-limiting conduit artery stenosis and microvascular dysfunction (Kern, et al., 2006) . Four different subtypes of adenosine receptors (AR) have been cloned and pharmacologically characterized -A 1 , A 2A , A 2B , and A 3 (Fredholm, et al., 2001; Shen, et al., 2005) . All are G-protein coupled and either inhibit (A 1 , A 3 , Gi/q) or stimulate (A 2A , A 2B , Gs) adenylyl cyclase (Fredholm, et al., 2001) . Adenosine predominantly dilates arterioles <100 µm in diameter (Duncker and Bache, 2008; Camici and Crea, 2007) . The vasodilatory mechanism involves A 2 activation and consequent elevation of cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA), resulting in vasodilation mainly via opening of ATP-sensitive K + (K ATP ) channels and voltage-dependent K + (K v ) channels (Bender, et al., 2009; Standen and Quayle, 1998; . Since A 1 decrease, A 2 increase cAMP (Fredholm, et al., 2001 ) and the roles of A 1 and A 2 subtypes are opposing (Sato, et al., 2005) , A 1 antagonism could positively modulate coronary vasodilation.
Tawfik et al. (Tawfik, et al., 2006) provided compelling evidence for A 1 regulation of CBF in an A 1 knockout mouse, but surprisingly studies have not been done on A 1 in large animals that more closely mimic human coronary physiology. AR may be responsible for the dysregulated adenosine-induced CBF in dyslipidemia.
Deployment of a stent in a flow-limiting coronary atherosclerotic lesion of a conduit coronary artery results in substantial improvement in functional capacity and quality of life.
However, almost one third of patients undergoing coronary stenting eventually experience recurrent angina (Abbate, et al., 2007) . Beyond in-stent thrombosis / restenosis that is the most common cause of post-stent angina (Abbate, et al., 2007) , downstream microvascular dysfunction has been implicated in causing exertional ischemia (Monnink, et al., 2003; Van Liebergen, et al., 1998; Kern, et al., 1999; Werner, et al., 2004; Camici and Crea, 2007) . This
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6 phenomenon was termed post-stent "iatrogenic coronary microvascular dysfunction" (Camici and Crea, 2007) . The mechanisms underlying microvascular dysfunction associated with stenting are unclear and deserve careful study. Patients with dyslipidemia exhibit impaired coronary flow reserve (Camici and Crea, 2007) , which has also been shown convincingly in dyslipidemic swine models by in vivo flow measures (Zhu, et al., 2009) . Because AR functions are highly specific based on AR subtype, vascular bed, and species (Shen, et al., 2005; , the vasodilatory effect of adenosine involves A 2 activation (Standen and Quayle, 1998; Bender, et al., 2009) , and A 1 and A 2 often mediate opposite effects of adenosine (Shen, et al., 2005) , the balance of A 1 and A 2 may contribute to impaired adenosine-induced CBF in chronic dyslipidemia after stenting.
We tested two central hypotheses in the present study: 1) A 1 antagonism potentiates coronary vasodilation in healthy control Ossabaw miniature swine, and 2) coronary stent deployment in dyslipidemic Ossabaw swine elicits impaired vasodilation to adenosine, which is associated with increased A 1 /A 2A expression in the microvessels downstream from stented conduit coronary arteries.
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Methods
Animal care and coronary stenting
All protocols involving animals were approved by an Institutional Animal Care and Use
Committee and complied fully with standards (National Research Council, 1996; Beaver, et al., 2001 ). Ten lean male Ossabaw miniature swine (age = 14±4 months) were fed a diet consisting of standard chow with 22% kcal from protein, 70% kcal from carbohydrates, and 8% kcal from fat. The data in Figs. 1, 2 and 3 were all obtained from those pigs. Another ten male Ossabaw swine (age = 14 months; n = 5/group) were randomized to lean control or dyslipidemic groups in the stenting study. The data in Figs. 4 and 5 were obtained from the pigs in the stenting study.
Please see the details in the flow diagram of the study in the Online Supplemental Figure 1 . The dyslipidemic pigs were fed chow supplemented with (percent by weight): cholesterol 2.0, coconut oil 17, corn oil 2.5, and sodium cholate 0.7. This mixture yielded a diet of 13% kcal from protein, 40% kcal from carbohydrates and 47% kcal from fat (Mokelke, et al., 2005) . Control and dyslipidemic groups were calorie-matched (3200 kcal/day) for 43 weeks until sacrifice, the intended experimental design to avoid development of obesity and metabolic syndrome Sturek, et al., 2007) . After 40 weeks on the diets, control and dyslipidemic pigs in the stenting study received a bare metal stent (2.5-4.0 mm diameter by 8 mm length; Express 2 , Boston Scientific, Minneapolis, MN, USA) in the circumflex coronary artery at a stent/artery ratio of 1.0 with optimal inflation pressure and recovered for 3 weeks before sacrifice as described previously Sturek, et al., 2007; Neeb, et al., 2010) . Swine received 325 mg aspirin as antiplatelet therapy starting the day before the stenting and continuing for 3 weeks after stenting until completion of the study. There was no evidence of microvascular embolization in all animals. Cephalexin (1000 mg) was given twice a day for six days following the stent procedure. All pigs were housed and fed in individual pens and provided a 12-hr light/12-hr dark cycle. Water was provided ad libitum.
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Coronary blood flow
The pigs were pre-anesthetized using telazol/xylazine and maintained using 2-4% isoflurane with oxygen via tracheal intubation and ventilation at a tidal volume of typically ~700 mL (10-15 mL/kg) and respiratory rate of 15/min. Heart rate, blood pressure, oxygen saturation, and electrocardiographic data were continuously monitored. These precautions confirm normal oxygen saturation and no hypercarbia or acidosis among the pigs based on blood gas and pH (ComboMap, Volcano Therapeutics, Inc., Rancho Cordova, CA, USA) was advanced down the circumflex artery under angiographic guidance and a non-branching section was selected for baseline and drug-induced flow measurements (Mokelke, et al., 2005; Sturek, et al., 2007; Neeb, et al., 2010) . Anatomical landmarks were noted in case the wire moves and requires re-positioning. In all lean control / stent (Fig. 4, n=5 ), all dyslipidemia / stent (Fig. 4,   n=5 ), lean / non-stent during A 2A -, A 2B -, A 3 -selective antagonist administration (Fig. 2, n=5 ) an intravascular ultrasound (IVUS; 3.2 F 30 MHz, Boston Scientific, Inc.) catheter was then advanced over the flow-wire and positioned in the circumflex to align the IVUS imaging transducer with the flow-wire tip to obtain accurate diameter measurement of the artery at the location where the flow velocity measurements were acquired (Mokelke, et al., 2005 Hyperemia was induced with 3 mL bolus doses of the endothelium-independent vasodilator adenosine (0.167, 0.33, and 1 µg/kg) given via the guiding catheter into the coronary artery as we described (Mokelke, et al., 2005) and is identical to clinical catheterization assessment in humans (Kern, et al., 2006) . Adenosine injection was followed by 10 mL saline
flush. Saline artifact was tested in each animal and, if present (usually less than 10% peak flow induced by adenosine), was subtracted from subsequent flow measurements. Peak average peak velocity (APV), heart rate, and blood pressure were recorded for each adenosine administration. Each APV value was calculated on-line using the automated data acquisition system as an average of instantaneous CBF velocity over 2 consecutive cardiac cycles.
Subsequent doses of adenosine were administered when APV, heart rate, and blood pressure had returned to baseline and stabilized, at which time the baseline parameters were again documented followed by the administration of the next adenosine dose. The effect of adenosine typically lasted 15-30 seconds.
The adenosine A 2 non-selective agonist CV1808 (10 antagonist, Tocris Science; MRS 1220, 10 -7 M, A 3 -selective antagonist, Tocris Science) at a rate of 1 mL/minute and was followed by concurrent bolus injection of adenosine. Vehicle control (1% DMSO) for DMPX was not used in parallel, which should be used for future experiments.
The vehicle controls for other reagents were either water or phosphate-buffered saline.
Continuous saline infusion was done between each constant infusion treatment to make sure the flow returned to baseline. The above-mentioned drug infusions were done in random order in each pig.
The analog Doppler signals were continuously digitized both as instantaneous CBF velocity and APV values. All flow data were stored on videotapes and personal computer for further off-line analysis. Data are also expressed as percent APV increase, which equals to
[peak APV-base APV] / base APV × 100. Volumetric CBF was calculated as: CBF (in mL/min) = (artery cross sectional area in cm 2 ) × (velocity in cm/s) × 0.5 × 60 s/min (Mokelke, et al., 2005) .
Vessel cross sectional area was calculated off-line from recorded IVUS images using the commercially available Sonos Intravascular Imaging software package. Angiography and IVUS showed no change in conduit artery diameter during any drug exposures, thus coronary flow velocity represented microvascular effects.
Plasma lipid assays
Venous blood samples were obtained following overnight fasting and were analyzed for triglyceride and total cholesterol [fractionated into high density lipoprotein (HDL) and low density lipoprotein (LDL) components] .
Real-time reverse transcription-polymerase chain reaction (Real-time RT-PCR)
RNA was extracted from coronary microvessels downstream of left circumflex coronary artery using Trizol (Invitrogen, Carlsbad, CA, USA), then treated with DNase (DNA free, Ambion, Austin, TX, USA) to remove contaminating genomic DNA, and analyzed by NanoDrop (Applied Biosystems). SYBRGreen Universal PCR Master Mix (Applied Biosystems) was used to detect A 2A , A 2B and A 3 gene expression followed by a dissociation curve to rule out nonspecific amplifications and primer-dimers. All results were normalized to the signal of 18s RNA, which was amplified in separate reactions using TaqMan Universal PCR Master Mix and TaqMan 18s Detection Reagents (Applied Biosystems).
Immunohistochemistry for AR
Left ventricular myocardium was preserved in 10% formalin solution, embedded in paraffin, sectioned, and treated with antibodies similar to our previous methods (Turk, et al., 2003) .
Primary polyclonal antibodies to A 1 and A 2A were applied and incubated overnight (1:100
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Data Analysis
Data were presented as means ± SEM. Statistical analysis was performed using commercially available software (SPSS version 12 and Prism version 4.0). Means of more than 2 groups were compared by one-way Analysis of Variance (ANOVA) with Least Significant Difference (LSD)
post-hoc analyses (by SPSS) or by 2-way ANOVA followed by Bonferroni post-test (by Prism).
Means of 2 groups were compared by student t-test (unpaired, two-tailed) . In all cases, p < 0.05 was considered statistically significant. 
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Results
Metabolic characteristics of control and dyslipidemic pigs with coronary stent deployment
Atherogenic diet resulted in significantly higher plasma total cholesterol, LDL, HDL, and LDL/HDL vs. control pigs fed standard chow diet (Table 1) . There were no differences in body weight, plasma triglycerides, fasting plasma insulin, fasting plasma glucose (Table 1) , or resting blood pressure ( Table 2 ). The plasma lipid profile defined the atherogenic diet fed group as dyslipidemic, but not having metabolic syndrome.
Contribution of A 2 to coronary blood flow regulation
The A 2 non-selective antagonist DMPX did not change base APV ( Figure 1A ), but abolished peak APV ( Figure 1B 
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14 2B) had modest effects on the adenosine-induced peak CBF compared to ZM241385 and no effect on base CBF (data not shown).
Contribution of A 1 to coronary blood flow
Constant infusion of the highly A 1 -selective antagonist DPCPX increased base APV without exogenous adenosine and increased peak APV response to adenosine at 1.0 µg/kg (Figure 3 ).
Intracoronary infusion of the highly A 1 -selective agonist CCPA did not alter base APV in the absence of exogenous adenosine nor peak APV response to adenosine (Figure 3) . Besides, there was no change of systemic parameters (i.e., blood pressure, heart rate) by the administration of AR agonists/antagonists in the non-stented lean control pigs (data not shown;
references (Mokelke, et al., 2005; ).
Comparison of coronary blood flow in control and dyslipidemic pigs undergoing stenting
There were no significant differences in hemodynamic characteristics across groups (Table 2 ), e.g. heart rate, mean arterial pressure, rate pressure product, and baseline CBF. The CBF (Figure 4 ) response to adenosine infusion at 0.167, 0.33, and 1.0 µg/kg was blunted in dyslipidemic vs. control pigs 3 weeks after stenting.
Expression of AR in coronary microvessels of control and dyslipidemic pigs 3-week after the stent deployment
A 1 , A 2A , and A 2B mRNA expression were upregulated >5-fold in coronary microvessels downstream from the stented left circumflex coronary artery in dyslipidemic compared to control pigs ( Figure  5A -C). A 3 mRNA level was not different between groups ( Figure 5D ).
Immunohistochemistry showed that although there was a trend for an increase in A 1 /A 2A protein expression in microvessels of hyperlipidemic (1.12±0.04) vs. lean control (1.0±0.05) pigs, the difference was not significant (P>0.05).
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Adenosine was shown as a vasodilator in porcine coronary microcirculation via activation of A 2A . The A 2B subtype was suggested to mediate vasodilation of adenosine in human small coronary arteries (Kemp and Cocks, 1999) , rat coronary circulation (Hinschen, et al., 2003) , and murine heart (Talukder, et al., 2003) . A 3 either inhibited or negatively modulated the vasodilatory effect of adenosine in mouse coronary circulation (Talukder, et al., 2002) . Studies in pigs (Wang, et al., 2005) and humans (Sato, et al., 2005) demonstrated A 1 mRNA and protein expression in coronary arterioles. In our current study, the non-selective A 2 antagonist DMPX did not change base APV ( Figure 1A) ; therefore A 2 were not tonically activated under normal, basal conditions. The A 2A -selective antagonist ZM241385 decreased peak CBF induced by exogenous adenosine (Figure 2A ), while A 2B -selective antagonist MRS1706 and A 3 -selective antagonist MRS1220 showed relatively little effect on CBF (Figure 2A -10 -7 M) of CCPA did not significantly change CBF (Tawfik, et al., 2006) .
Intracoronary infusion of CCPA at different concentrations may help to address that in the future. Third, since A 2 were not tonically activated, adenosine might not play an important role in maintenance of CBF under basal conditions, which was echoed by numerous studies done in normal hearts of dogs, swine, or humans under basal conditions or exercise hyperemia (Tune, et al., 2004; Tune, et al., 2002; Duncker and Bache, 2008) . However, adenosine played an important role in coronary vasodilation when the myocardium was ischemic or hypoxic, which is accompanied by abundant adenosine release (Tune, et al., 2004; Tune, et al., 2002; Sato, et al., 2005; Duncker and Bache, 2008) .
Compared to other animal models Ossabaw swine are predisposed to metabolic syndrome (Neeb, et al., 2010; Sturek, et al., 2007) and have substantial diffuse and focal, flowlimiting coronary atherosclerosis ; therefore, stenting in the Ossabaw swine is quite clinically relevant. Dyslipidemia in the present study was manifested as described previously (Bender, et al., 2009; Sturek, et al., 2007) . The reason why metabolic syndrome or obesity was avoided in the animals was to reduce the factors which may complicate the results, thus allowing the focus on dyslipidemia. Interestingly, A 1 , A 2A , and A 2B mRNAs were all upregulated in coronary microvessels distal to the stent in dyslipidemic swine receptor that overwhelms the vasodilatory effect mediated by A 2A activation. This is feasible because the affinity of adenosine for A 1 is higher than A 2 and the desensitization of A 1 is much slower than A 2 (t 1/2 = 10 hours vs. 20 minutes) (Stiles, 1992) . The net result is greater coupling of adenosine to A 1 than to A 2 to regulate CBF. Fourth, analogous to other disease states, vasodilator signaling pathways can be upregulated to partially compensate for increased vasoconstrictor or decreases in other vasodilator signaling pathways. For example, Ca 2+ -dependent K + channel function is upregulated in hypertension, but does not fully compensate for vasoconstrictor influences (Liu, et al., 1995) .
Adenosine has been found to increase post-ischemic recovery of function in humans in clinical interventions, such as angioplasty (Mubagwa and Flameng, 2001 ). These effects may be largely due to cardiac muscle A 1 . Further, the modulation/attenuation of heart rate (especially beta adrenergic stimulated) is also a classic finding (Belardinelli, et al., 2007) . There was no change of systemic parameters (i.e., blood pressure, heart rate) by the administration of AR agonists/antagonists (Mokelke, et al., 2005; ; therefore, under the conditions used for our flow measures (anesthetized, near resting heart rate and blood pressure) there was 
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18 no direct effect of adenosine on cardiac muscle to change cardiac metabolism and, in turn, coronary blood flow. These data do not entirely rule out a direct inhibitory effect of adenosine on cardiac myocytes at higher heart rates elicited by beta adrenergic stimulation and the possibility of different adenosine reduction of heart rate in lean control vs. dyslipidemic groups. Future studies should involve adrenergic provocation challenge with adenosine administration in the dyslipidemic pigs.
To our knowledge, this is one of the few studies examining the effects of stenting on coronary microcirculation in a porcine model of dyslipidemia . Since isoflurane was used in each group of animals during the procedures, its activation of coronary K ATP channels will elicit more baseline coronary vasodilation perhaps compared to other anesthetics (Kersten, et al., 1997) ; however, the differences between groups should be more due to the dyslipidemia and stent treatment than to isoflurane administration. Stenting and dyslipidemia are two possible causes for the dysregulated adenosine-induced CBF in dyslipidemic Ossabaw swine 3 weeks after stent deployment (Figure 4 ). Despite the findings that adenosine receptor-mediated coronary flow was impaired in dyslipidemic and metabolic syndrome patients (Camici and Crea, 2007) , as well as in dyslipidemic swine models (Zhu, et al., 2009) , previous study in our laboratory showed that diabetic dyslipidemic Yucatan (Mokelke, et al., 2005) and dyslipidemic Ossabaw pigs (Neeb, et al., 2010; Bender, et al., 2009 ) did not exhibit impaired microvascular dilation to adenosine. Coronary stenting has been shown to mechanically damage vascular cells in the target conduit artery segment and endothelium in peri-stent segments (Kim, et al., 2009; , and induces downstream microvascular dysfunction (Monnink, et al., 2003; Van Liebergen, et al., 1998; Kern, et al., 1999; Werner, et al., 2004; Camici and Crea, 2007) . However, none of those stent studies were done in a swine model of dyslipidemia prone to metabolic syndrome and the microcirculatory dysfunction was either attributable to endothelium (Monnink, et al., 2003) or unclarified (Van Liebergen, et al., 1998; Kern, et al., 1999; Werner, et al., 2004) . Further studies are needed to 
